Abrilumab (INN;[1] development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.[2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | integrin alpha-4 beta-7 |
| Clinical data | |
| Other names | AMG 181 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6362H9806N1686O2014S52 |
| Molar mass | 143803.34 g·mol−1 |
This drug was developed by MedImmune.
References
edit | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |